Semler Scientific, Inc. Q4 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

  • Core Business Performance: In Q4 2024, Semler Scientific reported revenues of $12.4 million, a decline of 18% compared to Q4 2023. The decrease is attributed to factors including the 2024 CMS rate announcement. Despite revenue pressure, operating income increased 40% to $3.5 million from $2.5 million in Q4 2023 due to a 29% reduction in operating expenses.
  • Annual Cash Generation: The company reported record cash generation from healthcare operations exceeding $24 million in 2024.
  • Bitcoin Treasury Strategy: Semler adopted Bitcoin as its primary treasury reserve asset in May 2024. Since then, the company has purchased 3,192 Bitcoins, now valued at over $300 million. These acquisitions were funded through operating cash flow, an at-the-market (ATM) equity program raising $119.6 million, proceeds from a $100 million convertible notes issuance, and monetization of a $3.5 million minority stake in Monarch Medical.
  • Bitcoin Performance: The yield on Bitcoin holdings was 152% since initiating the strategy, helping the company to generate $28.8 million in fair value gains during Q4 2024, contributing to a total quarterly net income of $29.2 million vs. $4.2 million in Q4 2023.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good afternoon, and welcome to the Semler Scientific’s Fourth Quarter and Full Year 2024 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is being recorded. Before we begin, Semler Scientific’s needs to remind you that certain comments made during this call may constitute forward-looking statements and are made pursuant to and within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 as amended. These include statements regarding the expectations for expansion of the business and development and marketing of additional products, including receipt and timing of an additional 510(k) clearance from QuantaFlo and our Bitcoin treasury strategy and plans to acquire additional Bitcoin. Such forward-looking statements are subject to both known and unknown risks and uncertainties that could cause actual results to differ materially from such statements. Those risks and uncertainties are described in the press release and our SEC filings. The forward-looking statements made today are as of the date of this call, and the company does not undertake any obligation to update the forward-looking statements. If you do not have a copy of today's press release, you may obtain one by visiting the Investor Relations page of the website, semlerscientific.com. I would now like to introduce Dr. Doug Murphy-Chutorian, CEO of Semler Scientific. Please go ahead, sir

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional